Advances in treatment of hyperkalemia in chronic kidney disease

Expert Opinion on Pharmacotherapy
Pantelis A SarafidisGeorge L Bakris

Abstract

Hyperkalemia is a frequent electrolyte disorder associated with life-threatening cardiac arrhythmias and sudden death. Patients prone to hyperkalemia have chronic kidney disease (CKD) either alone or in conjunction with diabetes or heart failure (HF). Although agents inhibiting the renin-angiotensin-aldosterone-system (RAAS) are currently the first-line treatments toward cardio- and nephroprotection, their administration often leads to potassium elevation in such patients and results in high rates of treatment discontinuation. This article provides an overview of factors interfering with potassium homeostasis and discusses emerging potassium-lowering therapies for long-term management of hyperkalemia. In recent randomized clinical studies, two new oral potassium-exchanging compounds, patiromer and sodium zirconium cyclosilicate, were shown to effectively normalize elevated serum potassium and chronically maintain potassium homeostasis in hyperkalemic patients treated with RAAS blockers. Both agents exhibit good tolerability and were not associated with serious adverse effects. Although additional research is required, these drugs are promising for lowering the risk of incident hyperkalemia associated with RAAS blockade use in p...Continue Reading

References

Jan 1, 1980·Kidney International·R A DeFronzo
Jun 1, 1995·The American Journal of Medicine·J R OsterL M Fishman
Oct 1, 1996·Annals of Emergency Medicine·F FentonJ Laut
Mar 10, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T KeilaniD Batlle
Sep 21, 2000·The American Journal of Medicine·M A Perazella
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·A Chrysostomou, G Becker
Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Aug 1, 1959·The American Journal of Physiology·D H SIMMONS, M AVEDON
Jun 18, 2004·Kidney International·Norman K Hollenberg
Aug 6, 2004·The New England Journal of Medicine·Biff F Palmer
Dec 23, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Pantelis A SarafidisGeorge L Bakris
Jun 19, 2007·Internal Medicine·Kenmei TakaichiYasumichi Mori
Jan 25, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S BombackPhilip J Klemmer
Jul 25, 2008·The New England Journal of Medicine·Nikolaus BüchnerBernhard K Krämer
Nov 14, 2008·Journal of the American Society of Nephrology : JASN·Olivier MoranneUNKNOWN NephroTest Study Group
Apr 18, 2009·Southern Medical Journal·C E McGowanS F Moss
Jun 24, 2009·Archives of Internal Medicine·Lisa M EinhornJeffrey C Fink
Sep 10, 2009·American Journal of Nephrology·Nitin KhoslaGeorge L Bakris
Sep 30, 2009·Archives of Internal Medicine·Joy M WeinbergUNKNOWN African American Study of Hypertension and Kidney Disease Collaborative Research Group
Oct 13, 2009·European Journal of Internal Medicine·I DrionH J G Bilo
Feb 13, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Matthew R Weir, Mark Rolfe
Feb 20, 2010·Journal of the American Society of Nephrology : JASN·Richard H SternsSreedevi Chennupati
Jul 3, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Matthew A WeirAmit X Garg
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Jan 31, 2012·Journal of the American Geriatrics Society·Paul E DrawzMahboob Rahman
Feb 22, 2012·The American Journal of Cardiology·Nishank JainSubhash Banerjee
May 19, 2012·Clinical Journal of the American Society of Nephrology : CJASN·Pantelis A SarafidisKatie Vinen
Jun 12, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Maura A WatsonChristina M Yuan
Oct 17, 2012·Nature Reviews. Nephrology·Sara S RoscioniHiddo J Lambers Heerspink
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Jan 17, 2013·The American Journal of Medicine·Ziv HarelChaim M Bell
Jul 31, 2013·Current Opinion in Nephrology and Hypertension·Paul A Welling
Aug 21, 2013·Seminars in Nephrology·Paul A Welling
Aug 27, 2013·International Journal of Clinical Pharmacy·Marianne A KuijvenhovenMirjam Crul

❮ Previous
Next ❯

Citations

Feb 18, 2016·Current Diabetes Reports·Collen Majewski, George L Bakris
Mar 19, 2016·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·M Camilleri
Sep 21, 2016·Expert Opinion on Drug Safety·Ada OffurumTanisha Gooden
Jan 26, 2018·Current Medical Research and Opinion·Keith A BettsEric Q Wu
Nov 6, 2017·Clinical Journal of the American Society of Nephrology : CJASN·David A BushinskyRobert Alpern
Mar 17, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Michał MiłekJaroslav Legáth
Jan 1, 2018·Current Pharmaceutical Design·Konstantinos V StavropoulosCharles J Faselis
Mar 9, 2019·Current Pharmaceutical Design·Pantelis A SarafidisAikaterini Papagianni
Aug 12, 2020·Journal of Human Hypertension·Alexia PiperidouPantelis Sarafidis
Oct 8, 2020·Current Opinion in Nephrology and Hypertension·John RizkKamyar Kalantar-Zadeh
Jan 15, 2021·Journal of Hypertension·Pantelis SarafidisUNKNOWN ‘Hypertension and the Kidney’ working group of the European Society of Hypertension (ESH) and the ‘European Renal and Cardio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Related Papers

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
David K Packham, Mikhail Kosiborod
Expert Opinion on Pharmacotherapy
Zubaid RafiquePhillip D Levy
Reviews in Cardiovascular Medicine
Peter A McCulloughNorman E Lepor
Nihon rinsho. Japanese journal of clinical medicine
Hideki KatoShunya Uchida
© 2021 Meta ULC. All rights reserved